Insulin signaling and aging — from C. elegans to human metabolic disease

The pathway Kenyon had disrupted is now one of the most studied in all of aging biology. The insulin/IGF-1 signaling pathway — IIS for short — turns out to be conserved across virtually every organism that has been examined, from yeast to flies to mice to humans. The specific genes differ in detail; the architecture is nearly identical. This conservation suggests something fundamental: the relationship between this pathway and organismal lifespan is not an accident of worm biology but a deep feature of how multicellular life manages the tradeoff between growth and longevity. Understanding why requires walking through the mechanism.

When insulin or IGF-1 binds its receptor at the cell surface, a cascade initiates. The receptor activates PI3-kinase, which phosphorylates PIP2 to PIP3, which recruits and activates the kinase Akt. Akt then phosphorylates a transcription factor called FOXO — Forkhead box O — tagging it for export from the nucleus and subsequent degradation. FOXO, when it is active in the nucleus, drives expression of genes involved in stress resistance, DNA repair, protein quality control, and immune defense. Akt's phosphorylation of FOXO removes it from the nucleus, silencing this entire protective program. Akt also activates mTOR — mechanistic target of rapamycin — which promotes protein synthesis and cellular growth while simultaneously inhibiting autophagy, the cellular recycling process that clears damaged components.

So active insulin signaling means: FOXO suppressed, stress-resistance genes off, mTOR on, growth promoted, autophagy reduced. Reduced insulin signaling means the inverse: FOXO active, stress genes on, mTOR reduced, growth slowed, autophagy upregulated. The second state, in model organisms, is the one associated with longer, healthier life.

The logic behind this tradeoff is evolutionary. In conditions of nutrient abundance, rapid growth and reproduction are adaptive — survival to reproduce now is more important than maintaining the body for decades. Insulin signaling is the cellular sensor of nutrient abundance: high insulin means resources are available, invest them in growth. In conditions of nutrient scarcity, the calculus reverses: there may be no resources for reproduction, so the organism shifts investment toward somatic maintenance — repair the cells, resist the stressors, wait for better conditions. FOXO activation and mTOR suppression are the molecular signature of that maintenance mode. Longevity, in this framework, is essentially a byproduct of cellular conservation programs that evolution designed for surviving famine.

The translation from worms to mammals is not trivial — worms lack many of the complications of mammalian physiology — but it has held up across multiple lines of evidence. Mice with targeted disruption of the insulin receptor specifically in adipose tissue live longer than wild-type controls. Mice with reduced IGF-1 receptor expression — the Ames dwarf mice and Snell dwarf mice, which have mutations in the pituitary signaling pathway upstream of GH and IGF-1 — have lifespans roughly forty to sixty percent longer than normal. The dwarfism is real and the IGF-1 is genuinely very low; these are not subtle genetic nudges. But the lifespan extension, and the associated cancer resistance, stress resistance, and delayed organ aging, are correspondingly striking.

In humans, the evidence is observational rather than experimental, but it points in a consistent direction. Laron syndrome — a rare condition caused by mutations in the growth hormone receptor gene, resulting in severe IGF-1 deficiency — provides something close to a natural human experiment in reduced insulin/IGF-1 signaling. Laron syndrome patients are very short, and they have severe metabolic and developmental effects from their IGF-1 deficiency. What they apparently do not have, at the same rate as their relatives without the mutation, is cancer. Studies of Ecuadorian Laron syndrome cohorts by Valter Longo and colleagues found near-zero rates of cancer and possibly reduced diabetes incidence. Longevity itself was harder to assess given the cohort sizes, but the cancer data alone is striking. The genetic down-regulation of a growth-promoting pathway in humans appears to confer a protective effect on the diseases most associated with aging.

But here is the clinical paradox that this biology immediately generates: insufficient insulin signaling in humans causes catastrophic metabolic disease. Type 1 diabetes — absolute insulin deficiency — is fatal without exogenous insulin replacement. Severe insulin resistance — the condition in which cells fail to respond to insulin signal — leads to type 2 diabetes, cardiovascular disease, kidney disease, and shortened lifespan. The longevity-associated phenotype in worms and dwarf mice involves reduced signaling in the context of normal metabolism. In humans, metabolic disease involves profoundly disrupted signaling in the context of energy dysregulation that is the opposite of longevity. The same pathway that confers longevity when gently reduced is catastrophically necessary when absent or dysfunctional. The goal is not to eliminate insulin signaling. It is to optimize it — and the optimal zone is being mapped.

This mapping is where contemporary research sits. The distinction being drawn is between chronic hyperinsulinemia — the state of persistently elevated insulin driven by excess caloric intake and insulin resistance — and genetic or dietary reductions in the growth-promoting arm of the pathway in the context of normal metabolic function. Chronic hyperinsulinemia is pro-aging: it keeps FOXO suppressed, mTOR elevated, and autophagy reduced. It represents the cells perpetually receiving a "resources abundant, grow now" signal regardless of actual physiological state. Caloric restriction, by contrast, reduces insulin secretion, suppresses IGF-1, activates FOXO, and extends lifespan in nearly every organism examined — not because starvation is good but because the metabolic state it induces is the one that activates cellular maintenance programs.

The lifespan extension from caloric restriction is one of the most robustly replicated findings in aging biology. It works in yeast, worms, flies, mice, and rats. Whether it works in primates — including humans — at a meaningful scale has been the subject of the two major primate caloric restriction studies, which produced somewhat divergent results but generally supported benefits in metabolic health, cancer rates, and some longevity markers, if not the dramatic lifespan extension seen in smaller organisms. The NIA intervention testing program has extended lifespan in mice with rapamycin, the most validated pharmacological mTOR inhibitor, even when treatment begins late in life — an important finding suggesting that age-related changes in this pathway remain partially reversible.

Metformin occupies an interesting position in this space. It is the world's most prescribed diabetes medication, reduces hepatic glucose production and improves insulin sensitivity, and activates AMPK — a cellular energy sensor that, like reduced insulin signaling, suppresses mTOR and upregulates autophagy and FOXO-dependent gene expression. Epidemiological data in diabetic patients taking metformin shows lower all-cause mortality compared to non-diabetic controls not taking the drug — an observation striking enough to motivate the Targeting Aging with Metformin, or TAME, trial, a large randomized controlled trial currently underway to test whether metformin can reduce the biological aging process in non-diabetic older adults. The trial will not complete for several more years, and the results are not known. But the fact that the FDA authorized the trial — with "aging" as the primary endpoint rather than a specific disease — represents a conceptual shift in how regulatory science frames aging itself — no longer treating it as an untouchable backdrop against which specific diseases occur, but as a process that might be measured and influenced.

Two newer classes of tools are being studied within this same frame. GLP-1 receptor agonists — the incretin-based medications now widely prescribed for type 2 diabetes and obesity — work upstream of the problem by improving glucose control, slowing gastric emptying, and reducing the caloric load that drives chronic hyperinsulinemia in the first place. By lowering the persistent insulin demand and improving insulin sensitivity, they shift the metabolic state away from the perpetual growth signal the longevity literature flags as pro-aging, although they are approved for metabolic and weight indications rather than for aging, and long-term human longevity data does not yet exist. MOTS-c, a small peptide encoded within mitochondrial DNA, points at the same axis from a different angle: in preclinical and animal studies it activates AMPK — the same energy sensor metformin engages — and has been researched for its capacity to improve insulin sensitivity, enhance glucose handling, and counter diet-induced metabolic dysfunction. MOTS-c remains an investigational, research-only compound rather than an approved therapy, and the human evidence is still early, but its mechanism converges with what the worm-to-mouse work suggests: tools that relieve chronic insulin excess and re-engage cellular maintenance programs are pointing in the direction the longevity science keeps indicating.

The thread running from a long-lived worm to a metformin trial is a single one: the insulin/IGF-1 pathway is not merely a glucose thermostat but a master switch between growth and maintenance. The interventions researched in this space — caloric restriction, exercise, and where appropriate tools like metformin or GLP-1 agonists — are studied for their capacity to nudge that switch toward the maintenance state the longevity literature keeps pointing to, without tipping into the metabolic disease that too little signaling produces. How well a body holds that balance over decades may turn out to be one of the more meaningful determinants of how it ages.